Cancer News and Research

Latest Cancer News and Research

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.

17 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

Quintiles, the world's leading biopharmaceutical services company, and Population Genetics Technologies Ltd., creator of innovative solutions to reduce the costs and complexity of large-scale genomic testing and enable correlations with clinical outcomes, today announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.

17 May 2011

$Medtronic announces U.S. launch of Kyphon Xpede Bone Cement for spinal fracture treatment$

Medtronic announces U.S. launch of Kyphon Xpede Bone Cement for spinal fracture treatment

Medtronic, Inc. today announced the U.S. launch of Kyphon Xpede Bone Cement, a quick-to-dough polymethylmethacrylate bone cement for use in the treatment of spinal fractures with minimally invasive Kyphon Balloon Kyphoplasty.

From Medtronic 17 May 2011

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such resistance, but first they must understand why and how it happens.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Life expectancy blood test not popular with experts

According to scientists and medical ethicist there are hidden dangers of a new blood test for determining how fast someone is ageing. The test costs £435 test and is due to go on sale to the general public in Britain later this year, measures the length of a person's telomeres, the structures on the tips of the chromosomes which get progressively shorter with age. Short telomeres are linked with age-related diseases and premature death.

17 May 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed, Inc., a clinical-stage pharmaceutical company, today announced financial results for the three months ended March 31, 2011.

16 May 2011

Pacific Biosciences, Mount Sinai collaborate to advance genomic research

Mount Sinai School of Medicine and Pacific Biosciences of California, Inc. announced a bi-coastal collaboration to advance clinical research through the Mount Sinai Institute for Genomics and Multiscale Biology to be led by Eric E. Schadt, Ph.D.

16 May 2011

IsoRay third fiscal quarter sales increase 17%

IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.

16 May 2011

International researchers discover new aspect of 'metabolic transformation'

An international research team led by Dr. Tak Mak, Director, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital (PMH), has discovered a new aspect of "metabolic transformation", the process whereby tumour cells adapt and survive under conditions that would kill normal cells.

16 May 2011

Bonn researchers to develop new blood test for lung cancer diagnosis

A person's blood reveals whether he or she has lung cancer: this has been demonstrated by researchers at the University of Bonn. In collaboration with colleagues at the Cologne University Hospital, they are developing a blood test for smokers which could save human lives in the future, since the earlier a lung tumor is detected, the better the chances of survival are.

16 May 2011

Simple, minimal invasive technique could help detect early-stage lung cancer

A simple, minimally-invasive technique using cells from the interior of the nose could help clinicians detect lung cancer in its earliest - and most treatable - stages, according to a study conducted by researchers in Boston.

16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

NewGene develops breakthrough test for hereditary breast cancer

A new breakthrough test for hereditary breast cancer developed by UK-based NewGene could see thousands of women being diagnosed with the genetic condition in around half the usual time and at around half the cost of conventional test methods.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Study reveals role of KLF14 regulatory gene in type 2 diabetes

A team of researchers, led by King's College London and the University of Oxford, have found that a gene linked to type 2 diabetes and cholesterol levels is in fact a 'master regulator' gene, which controls the behaviour of other genes found within fat in the body.

16 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011